These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17715257)

  • 1. Clinical decision making and the expected value of information.
    Willan AR
    Clin Trials; 2007; 4(3):279-85. PubMed ID: 17715257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of information methods for planning and analyzing clinical studies optimize decision making and research planning.
    Willan AR; Goeree R; Boutis K
    J Clin Epidemiol; 2012 Aug; 65(8):870-6. PubMed ID: 22609138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain].
    Hart WM; Rubio-Terrés C; Margalet Fernández I; González Juanatey JR
    An Med Interna; 2002 Oct; 19(10):515-20. PubMed ID: 12481494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic impact of HOPE.
    Ostergren JB; Björholt I; Andersson F; Kahan T
    Int J Clin Pract Suppl; 2001 Jan; (117):19-21. PubMed ID: 11715354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More than just hype.
    Yusuf S; Dagenais G
    CMAJ; 2003 Jun; 168(13):1646; author reply 1647-8. PubMed ID: 12821614
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate.
    Willan AR; Kowgier ME
    Health Econ; 2008 Jul; 17(7):777-91. PubMed ID: 17764096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.
    Lamy A; Yusuf S; Pogue J; Gafni A;
    Circulation; 2003 Feb; 107(7):960-5. PubMed ID: 12600907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?
    Grover SA; Coupal L; Lowensteyn I
    Can J Cardiol; 2008 Apr; 24(4):261-6. PubMed ID: 18401465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
    Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
    Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
    Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
    J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experiences with the realisation of innovative study designs using the example of the HOPE-study].
    Rangoonwala B
    Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S82-5. PubMed ID: 15988674
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.